Liprimar

Atorvastatin, the active ingredient in Liprimar, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol and triglyceride levels and is used in adults at risk of cardiovascular disease. GNH USA supplies Liprimar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liprimar (atorvastatin) acts on lipid metabolism pathways to manage dyslipidaemia and reduce cardiovascular risk. Hypercholesterolemia: lowers total and LDL cholesterol levels. Hyperlipidemia: reduces triglycerides and raises HDL cholesterol. Primary prevention of cardiovascular disease: decreases the likelihood of first‑time heart attack or stroke. Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established disease.

Adverse reactions may occur with atorvastatin therapy.

Common Side Effects: - Muscle aches or weakness (myalgia). - Headache. - Gastrointestinal discomfort such as nausea or abdominal pain. - Elevated liver enzymes. - Diarrhoea. - Dizziness.

Serious or Rare Side Effects: - Rhabdomyolysis (severe muscle breakdown). - Acute liver injury or hepatitis. - Severe allergic reactions (rash, angioedema, anaphylaxis). - New onset diabetes mellitus. - Cognitive impairment (memory loss, confusion).

Before initiating therapy, consider the following precautions. - Pregnancy: contraindicated (Category X) – do not use during pregnancy. - Breastfeeding: avoid use as it may pass into milk. - Liver disease: assess hepatic function; avoid if active liver disease is present. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Atorvastatin may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) – risk of severe myopathy. - Gemfibrozil – increased risk of rhabdomyolysis. - Cyclosporine – heightened statin exposure and muscle toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminium or magnesium – may reduce absorption. - Warfarin – may enhance anticoagulant effect, monitor INR. - Niacin – may increase risk of muscle-related side effects. - Digoxin – may increase serum digoxin levels. - Grapefruit juice – can modestly raise atorvastatin concentrations.